Ranbaxy Shutters Liquids Unit At Gloversville Citing Rationalization; Keeps Optimism On Lipitor Exclusivity
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Calling it a process of rationalization, Ranbaxy Laboratories Ltd. announced that it has shut down the liquids manufacturing facility at its U.S.-based Ohm Labs unit based in Gloversville, New York. Ranbaxy Managing Director Arun Sawhney told analysts and investors during an Aug. 5 conference call to detail second quarter earnings that the company continuously looks at its global plants to maximize efficiencies. In the past, Ranbaxy has eased out from manufacturing operations in China and Vietnam